|
|
Fos47 |
|
Vaxjo ID |
158 |
|
Vaccine Adjuvant Name |
Fos47 |
|
Adjuvant VO ID |
VO_0005291
|
|
Description |
small molecule and Combination adjuvant using tlr4 and tlr7 agonist, induced mixed Th1/Th2 profile |
|
Stage of Development |
Research |
|
Location Licensed |
US (UCSD) |
|
Host Species for Testing |
3 |
|
Components |
Fos47 comprises small molecule TLR4 (2B182C) and TLR7 (1V270) agonists in a liposomal formulation |
|
Storage |
4C, may need sonication after prolonged storage |
|
Preparation |
Liposomes were prepared using the thin lipid -film rehydration method and rehydrated with 10 mM sodium phosphate at pH 7.1 with Fos47 |
|
Function |
enhanced germinal center reactions in the draining lymph nodes, induced sustained and balanced systemic Th1/Th2 responses, and provided homologous protection from lethal infections |
| References |
(Carson, 2023): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=5]
Goff et al., 2017: Goff PH, Hayashi T, He W, Yao S, Cottam HB, Tan GS, Crain B, Krammer F, Messer K, Pu M, Carson DA, Palese P, Corr M. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Journal of virology. 2017; 91(19); . [PubMed: 28724768].
|
|
